Cancer clinical trials in the region Bourgogne-Franche-Comté

150 currently recruiting clinical trials

If you are a doctor and would like find matching clinical trials for you patients, create an account or log in

If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial

Early Access Lung cancer

Accès précoce pré-AMM– RYBREVANT 350 mg

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy

Systemic Treatment-Naive

Janssen

Early Access Lung cancer

Accès précoce pré-AMM– RYBREVANT 350 mg

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive

Janssen

Early Access Lung cancer

Accès précoce pré-AMM– TAGRISSO (osimertinib)

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy

AstraZeneca

Early Access Lung cancer

Accès précoce – OPDIVO (nivolumab)

NSCLC (Non-Small Cell Lung Cancer) Localized PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive

ALK EGFR

Bristol-Myers Squibb

Early Access Lung cancer

Accès précoce pré-AMM– IMFINZI (durvalumab)

SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy

AstraZeneca

Phase 3 Lung cancer

#NCT05555732

[TROPION-Lung07] DATOPOTAMAB DERUXTECAN et PEMBROLIZUMAB avec ou sans chimiothérapie au platine dans le cancer du poumon non à petites cellules

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic PDL1 Negative (< 1%) PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) None Systemic Treatment-Naive

Immunotherapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Immunotherapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)

Centre Hospitalier Universitaire de Besançon (Besançon)

Daiichi Sankyo

Phase 3 Lung cancer

#NCT05078047

[MOIO] Étude comparant l'administration standard d'une immunothérapie (IO) vs la même IO administrée tous les 3 mois chez des patients en réponse après 6 mois d'IO standard

Locally Advanced Metastatic Immunotherapy

CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon )

UNICANCER

Phase 3 Stomach and esophageal cancer

#NCT06346392

[CLARITY Gastric 01] Comparaison de l'AZD0901 avec le choix thérapeutique de l'investigateur chez des patients atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne avancé ou métastatique, exprimant la Claudine 18.2, en deuxième ligne ou plus

Stomach Oesogastric junction Esophagus Adenocarcinoma Locally Advanced Metastatic Claudin 18.2 1 2 3 or more Chemotherapy

HER2 Systemic Treatment-Naive

Centre Hospitalier Universitaire de Besançon (Besançon)

AstraZeneca

Phase 3 Colon cancer Rectal cancer

#NCT06252649

[CodeBreaK 301] Étude du SOTORASIB , du PANITUMUMAB et du FOLFIRI versus FOLFIRI avec ou sans BEVACIZUMAB chez des participants naïfs de traitement atteints d'un cancer colorectal métastatique avec mutation KRAS p.G12C

Adenocarcinoma Metastatic KRAS G12C None Systemic Treatment-Naive

Targeted therapy Targeted therapy

Centre hospitalier universitaire François Mitterrand (Dijon)

Amgen

Phase 3 Endometrial cancer

#NCT06132958

[TroFuse-005] SACITUZUMAB TIRUMOTECAN dans le cancer de l'endomètre après traitement au platine et après immunothérapie

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Locally Advanced Metastatic 1 2 3 or more Immunotherapy Chemotherapy

Antibody Drug Conjugates (ADC)

Centre Hospitalier Universitaire de Besançon (Besançon)

Merck Sharp & Dohme LLC